Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
ClearPoint Neuro, Inc.
Exec Compensation
confidence 75%
filed 2026-05-21
Item 5.02
The filing's primary disclosure is stockholder approval of the "Seventh Amended and Restated 2013 Incentive Compensation Plan," which is a material compensatory arrangement affecting equity grants and performance awards for officers and directors. While the section also includes routine committee appointments and board composition changes, the substantive Item 5.02(e) event centers on the Plan adoption, making exec_compensation the most salient classification.
View raw filing on EDGAR →
ClearPoint Neuro, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is Item 5.07 disclosing the results of an Annual Meeting of stockholders. The filing presents voting results for four proposals: election of seven directors, ratification of auditors (Cherry Bekaert LLP), advisory approval of executive compensation, and approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan. All proposals were approved. This is a standard shareholder vote results disclosure that materially informs investors of governance and compensation decisions.
View raw filing on EDGAR →
Alphabet Inc.
Other material
confidence 72%
filed 2026-05-21
Item 8.01
Alphabet closed a ¥576.9 billion (~$3.8 billion USD equivalent) underwritten public offering of Japanese yen-denominated senior notes across seven tranches with maturities from 2029 to 2066. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the standard M&A, dilutive equity issuance, or other specific event categories—it is a debt financing activity disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
Victory Capital Holdings, Inc.
Other material
confidence 65%
filed 2026-05-21
Item 1.01
Victory Capital entered into a Seventh Amendment to its Credit Agreement on May 18, 2026, refinancing existing term loans with repriced term loans at lower interest rates (SOFR plus 1.75% or alternate base rate plus 0.75%). While this is a material definitive agreement affecting the company's debt structure and financing costs, it does not fit cleanly into the more specific event categories—it is neither a new acquisition (ma_activity), a covenant breach, nor a going-concern disclosure. The refinancing is material to investors as it affects the company's cost of capital and financial obligations, but the taxonomy lacks a dedicated "debt refinancing" category.
View raw filing on EDGAR →
Victory Capital Holdings, Inc.
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 references Item 1.01 (Business Combinations) by incorporation, indicating a material acquisition or merger that creates direct financial obligations. Without the full Item 1.01 text, the specific nature of the transaction cannot be determined—it could be an M&A activity, a debt issuance, or another material obligation. The reference structure suggests a significant transaction, but the event type cannot be confidently assigned without seeing the underlying Item 1.01 disclosure.
View raw filing on EDGAR →
GATX CORP
Other material
confidence 72%
filed 2026-05-21
Item 1.01
GATX Corporation entered into Amendment No. 1 to its Five Year Credit Agreement on May 21, 2026, extending the termination date by one year (to May 21, 2031) and reducing borrowing margins and facility fees. While this is a material amendment to a significant credit facility, it does not fit cleanly into the M&A activity category (which covers acquisitions, dispositions, mergers, or changes of control). The amendment is a refinancing/restructuring of existing debt terms rather than a new material acquisition or disposition, making "other_material" the most appropriate classification for this material but non-categorical event.
View raw filing on EDGAR →
GATX CORP
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 discloses creation of a direct financial obligation via a Credit Agreement and Amendment, which typically signals a material financing event. However, the section provides no substantive details—it merely incorporates Item 1.01 by reference. Without visibility into Item 1.01's content (e.g., whether this is a routine credit facility renewal, a covenant breach triggering acceleration, or a material debt issuance), the specific event type cannot be reliably determined. The disclosure is material to investors as a financial obligation, but the event classification remains ambiguous.
View raw filing on EDGAR →
COPART INC
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses Copart's financial results for the third quarter of fiscal year 2026 (ended April 30, 2026) via a press release issued on May 21, 2026 and furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's operational and financial performance.
View raw filing on EDGAR →
TPG RE Finance Trust, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from TPG RE Finance Trust's 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing reports voting outcomes for three proposals: election of eight directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on executive compensation. The detailed vote tallies (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal are the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
REINSURANCE GROUP OF AMERICA INC
Exec Compensation
confidence 85%
filed 2026-05-21
Item 5.02
The disclosure reports shareholder approval of an amendment and restatement of the Company's Employee Stock Purchase Plan (ESPP), which increases authorized shares from 100,000 to 400,000 (a 300,000 share increase). This is a compensatory arrangement affecting employees and is material to investors as it expands equity dilution and employee compensation capacity. The event centers on a compensation plan amendment approved at the annual meeting, fitting the exec_compensation category.
View raw filing on EDGAR →
REINSURANCE GROUP OF AMERICA INC
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from the Annual Meeting held on May 20, 2026. The filing reports the outcomes of four separate votes: election of eleven directors, advisory vote on named executive officer compensation, approval of the Amended & Restated Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as independent auditor. The detailed vote tallies (For, Against, Abstain/Withheld, and Broker Non-Votes) for each matter are the hallmark of Item 5.07 disclosure and are material to investors assessing corporate governance and shareholder approval of key company matters.
View raw filing on EDGAR →
TransMedics Group, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 disclosure reports the results of TransMedics' 2026 Annual Meeting of Shareholders held on May 20, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, amendment to the 2019 Stock Incentive Plan, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies for each proposal are material to shareholders' understanding of governance and corporate direction.
View raw filing on EDGAR →
BrightSpring Health Services, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from BrightSpring's 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing reports the outcomes of three proposals: election of three Class II directors (Olivia Kirtley, Max Lin, and Steve Miller), ratification of KPMG LLP as independent auditor, and an advisory vote on executive compensation. All three items were approved. This is a material event as it reflects shareholder approval of board composition and auditor selection, which are fundamental governance matters affecting investor confidence.
View raw filing on EDGAR →
Hyperfine, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This 8-K Item 5.07 discloses the results of Hyperfine's 2026 annual meeting of stockholders held on May 21, 2026, including the reelection of five board directors (Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.) and the ratification of Grant Thornton LLP as independent auditor, with detailed vote tallies for each proposal. The disclosure of shareholder meeting results is a material governance event that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →
FLOWERS FOODS INC
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing financial condition and results of operations for the 16-week period ended April 25, 2026, filed under Item 2.02. This is a classic earnings release disclosure, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →
FLOWERS FOODS INC
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The filing discloses a material reset of the company's dividend policy, reducing the annual rate to $0.50 per share and declaring a quarterly dividend of $0.1250 per share. While dividend declarations are routine for mature companies, a "reset" of the dividend rate suggests a significant policy change that would affect shareholder returns and investor expectations. This does not fit neatly into the more specific event categories (it is not exec compensation, M&A, or a financial restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
Lumen Technologies, Inc.
M&A activity
confidence 75%
filed 2026-05-21
Item 1.01
Lumen Technologies' subsidiary Level 3 Financing completed a $1.0 billion offering of senior notes and entered into an indenture on May 21, 2026. While this is primarily a debt financing transaction rather than a traditional M&A event, Item 1.01 covers "Entry into a Material Definitive Agreement," and the $1 billion principal amount, senior unsecured status with guarantees from parent and material subsidiaries, and use of proceeds to fund concurrent tender offers constitute a material capital structure transaction. The scale and complexity of the transaction (including change-of-control provisions and restrictive covenants) make it material to investors assessing the registrant's financial position and obligations.
View raw filing on EDGAR →
Lumen Technologies, Inc.
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 discloses creation of a direct financial obligation, and the section incorporates Item 1.01 by reference. However, the provided text contains only boilerplate language about exhibits and does not specify the nature, amount, or terms of the obligation itself. Without access to Item 1.01 or the referenced exhibits, the specific event type (e.g., debt issuance, covenant breach, or other financing arrangement) cannot be reliably determined. The reference to "Notes" and "Level 3 Financing" suggests a material financing transaction, but the sparse disclosure here warrants a conservative classification.
View raw filing on EDGAR →
Xometry, Inc.
Exec appointment
confidence 95%
filed 2026-05-21
Item 5.02
The filing discloses the appointment of Lukas Biewald to the Board of Directors effective May 20, 2026, and his concurrent appointment to the Nominating and Corporate Governance Committee. While the disclosure includes compensatory arrangements (RSU awards and cash retainers), the principal disclosed action is the appointment of a director to the Board, making exec_appointment the most salient event type. The materiality is clear given the board-level appointment and associated equity compensation.
View raw filing on EDGAR →
Xometry, Inc.
Exec appointment
confidence 95%
filed 2026-05-21
Item 7.01
The filing discloses the appointment of Mr. Biewald to the Board of Directors via press release on May 21, 2026. Board appointments are material events affecting the composition and governance of the registrant and would inform a reasonable investor's assessment of the company's leadership and oversight structure.
View raw filing on EDGAR →
Baker Hughes Co
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Baker Hughes discloses a material acquisition of Chart Industries pursuant to a Merger Agreement dated July 28, 2025. The filing reports progress toward closing: completion of pre-notification with the European Commission and filing of a Form CO on May 21, 2026, initiating Phase I regulatory review. The company expects the merger to close in July 2026, subject to regulatory approvals and customary closing conditions. This is a significant M&A transaction requiring SEC disclosure under Item 8.01.
View raw filing on EDGAR →
Research Alliance Corp III
M&A activity
confidence 75%
filed 2026-05-21
Item 1.01
This disclosure describes the entry into multiple material definitive agreements in connection with Research Alliance Corp III's IPO consummation on May 21, 2026, including an Underwriting Agreement, Investment Management Trust Agreement, and Private Placement Shares Purchase Agreement. While technically an IPO rather than a traditional M&A transaction, the filing is structured as Item 1.01 (Entry into Material Definitive Agreement) and involves a significant capital-raising event and structural agreements that establish the company's framework for future business combinations. The $75 million in gross IPO proceeds and the trust account structure are material to investors.
View raw filing on EDGAR →
Research Alliance Corp III
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
This disclosure describes a private placement of 275,000 Class A ordinary shares to the Sponsor at $10.00 per share, generating $2.75 million in proceeds, issued pursuant to Section 4(a)(2) of the Securities Act. The transaction is a classic dilutive issuance of unregistered equity securities concurrent with an IPO, which materially affects the capital structure and ownership of the registrant.
View raw filing on EDGAR →
Research Alliance Corp III
Exec appointment
confidence 95%
filed 2026-05-21
Item 5.02
The disclosure centers on the appointment of Michael F. MacLean and Timothy J. Miller to the Board of Directors effective May 19, 2026, in connection with the Company's IPO, along with their concurrent appointments to three Board committees (Audit, Nominating, and Compensation). While the section also discloses compensatory arrangements (Class B share transfers), the principal action disclosed is the appointment of these two directors and their committee assignments, making exec_appointment the most salient classification.
View raw filing on EDGAR →
Research Alliance Corp III
Other material
confidence 65%
filed 2026-05-21
Item 5.03
The company adopted an Amended and Restated Memorandum and Articles of Association in connection with its IPO on May 19, 2026. While Item 5.03 disclosures are typically routine governance matters, the adoption of new governing documents concurrent with an IPO is material to investors as it establishes the company's post-IPO governance structure and shareholder rights. However, this is a structural/governance event rather than a specific operational or financial event type in the taxonomy, warranting classification as other_material.
View raw filing on EDGAR →
Research Alliance Corp III
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The filing discloses pricing of an IPO announced via press release on May 19, 2026. While IPO pricing is a material capital-raising event affecting the registrant's equity structure and investor base, it does not fit neatly into the standard 8-K taxonomy (not an earnings release, M&A activity, or other predefined category). This is classified as other_material because it represents a significant corporate event that would materially affect a reasonable investor's assessment of the company, but lacks a more specific event type in the taxonomy.
View raw filing on EDGAR →
CHART INDUSTRIES INC
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Chart Industries disclosed a material acquisition by Baker Hughes under Item 8.01 (Other Events). The filing reports that on July 28, 2025, Chart entered into an Agreement and Plan of Merger with Baker Hughes, whereby Chart will be acquired and survive as an indirect wholly owned subsidiary of Baker Hughes. The disclosure further notes that Baker Hughes filed a Form CO with the European Commission on May 21, 2026, initiating Phase I regulatory review, with expected closing in July 2026. This constitutes a material M&A transaction requiring disclosure under Item 1.01 or analogous provisions, though reported here under Item 8.01 as a regulatory milestone update.
View raw filing on EDGAR →
Phathom Pharmaceuticals, Inc.
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from Phathom Pharmaceuticals' 2026 Annual Meeting held on May 19, 2026. The filing presents final voting tallies for three proposals: election of Class I directors (Steven Basta, Theodore R. Schroeder, Mark Stenhouse), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. This is a routine but material Item 5.07 disclosure required by SEC rules.
View raw filing on EDGAR →
URBAN OUTFITTERS INC
Earnings release
confidence 95%
filed 2026-05-21
Item 8.01
The filing explicitly states that Urban Outfitters issued an earnings release on May 20, 2026, disclosing "material non-public information regarding the Company's earnings for the three months ended April 30, 2026." This is a direct disclosure of quarterly financial results, which is the core definition of an earnings_release event. The characterization as "material non-public information" and the attachment of the earnings release as Exhibit 99.1 confirm this classification.
View raw filing on EDGAR →
River Financial Corp
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from River Financial Corp's 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing presents the election of nine director nominees with detailed vote tallies (Votes For, Against, Abstain, and Broker non-votes) for each candidate, which is the quintessential content of Item 5.07 shareholder vote results disclosures. Director elections are material governance events affecting investor assessment of board composition and control.
View raw filing on EDGAR →
Seagate Technology Holdings plc
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 3.02
Item 3.02 discloses unregistered sales of equity securities in private placements under Section 4(a)(2) of the Securities Act. The filing explicitly states that "ordinary shares to be issued in the Exchanges will be issued pursuant to the exemption from the registration requirements," which is the hallmark of a dilutive issuance. This is material to investors as it affects share count and ownership dilution.
View raw filing on EDGAR →
Seagate Technology Holdings plc
Dilutive issuance
confidence 72%
filed 2026-05-21
Item 8.01
Seagate entered into exchange agreements to convert $185.908 million principal amount of exchangeable notes into cash and ordinary shares. This is a dilutive issuance of equity securities in exchange for debt retirement, materially affecting the capital structure and shareholder equity. While the exact share count is to be determined over a trading day period, the transaction involves a significant equity component that would dilute existing shareholders.
View raw filing on EDGAR →
BCB BANCORP INC
Exec departure
confidence 75%
filed 2026-05-21
Item 5.02
Michael A. Shriner's separation from his positions as President and Chief Executive Officer of BCB Bancorp and its subsidiary, along with his departure from both boards, is the principal disclosed action. While the filing also mentions Ryan Blake's appointment as Interim President and CEO, the prose centers on Shriner's departure as the triggering event. The departure of a CEO is material to investors assessing the registrant's leadership and governance.
View raw filing on EDGAR →
DEVON ENERGY CORP/DE
M&A activity
confidence 85%
filed 2026-05-21
Item 7.01
Item 7.01 discloses a press release issued by Devon Energy "in connection with the acquisition described in Item 8.01 below." Although Item 7.01 itself is a Regulation FD disclosure (non-binding), the substance of the filing centers on an acquisition event. The reference to Item 8.01 (which typically covers material acquisitions under Item 1.01 or 2.01) and the issuance of a press release about the acquisition indicate this is a material M&A activity disclosure. Acquisitions are presumptively material to investors.
View raw filing on EDGAR →
DEVON ENERGY CORP/DE
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Devon completed acquisition of 16,300 net undeveloped acres in the Delaware Basin for approximately $2.6 billion, representing a material acquisition of oil and gas assets. The substantial purchase price and acreage volume constitute a material transaction that would affect investor assessment of the company's asset base and capital deployment strategy.
View raw filing on EDGAR →
Corbus Pharmaceuticals Holdings, Inc.
Exec appointment
confidence 75%
filed 2026-05-21
Item 1.01
The filing discloses Corbus Pharmaceuticals' entry into an employment agreement with Nishant Saxena effective May 21, 2026, appointing him as Chief Business Officer with a two-year term. While the Item 1.01 caption references "Material Definitive Agreement," the substance centers on the appointment of a named executive officer with significant compensation (base salary $470,000, equity grants of 192,300 stock options and 58,300 RSUs, and severance provisions). This is material to investors as a C-suite appointment affecting corporate governance and strategy.
View raw filing on EDGAR →
Corbus Pharmaceuticals Holdings, Inc.
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
The disclosure centers on equity compensation awards granted to Brent Pfeiffenberger in connection with his Board appointment: a nonqualified stock option for 24,700 shares and a restricted stock unit award for 7,500 shares, both vesting over three years. While the section mentions his appointment, the substantive disclosure focuses on the compensatory arrangements themselves, making this an exec_compensation event rather than exec_appointment.
View raw filing on EDGAR →
Corbus Pharmaceuticals Holdings, Inc.
Exec appointment
confidence 92%
filed 2026-05-21
Item 7.01
The filing discloses the appointment of Mr. Saxena as Chief Business Officer, which is a material executive appointment. While the Item 7.01 disclosure also mentions a conference call regarding clinical data, the principal disclosed action is the appointment of a named executive to a senior officer role. Executive appointments to C-suite positions materially affect investor assessment of company leadership and strategy.
View raw filing on EDGAR →
Orthofix Medical Inc.
Other material
confidence 75%
filed 2026-05-21
Item 7.01
The FDA reclassified non-invasive bone growth stimulators from Class III to Class II, triggering CMS reimbursement changes that reduce Medicare reimbursement by approximately 10% for HCPCS codes E0747, E0748, and E0760. This regulatory action materially impacts Orthofix's financial outlook, forcing the company to lower full-year 2026 net sales guidance to $838–$848 million and adjusted EBITDA to $90–$93 million, and to withdraw its three-year financial targets. While this is a material event affecting investor assessment, it does not fit neatly into the more specific categories (it is neither a restatement, impairment, covenant breach, nor litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
UNIVERSAL HEALTH SERVICES INC
Exec departure
confidence 95%
filed 2026-05-21
Item 5.02
Matthew J. Peterson, Executive Vice President and President of Behavioral Health, resigned effective June 19, 2026, after seven years with the company. While the filing also addresses compensatory arrangements (forfeiture of unvested equity and termination of benefits), the principal disclosed action is Peterson's departure from a senior executive role overseeing a major division. The CEO will assume interim responsibilities while a permanent replacement is sought, indicating material operational impact.
View raw filing on EDGAR →
ERP OPERATING LTD PARTNERSHIP
M&A activity
confidence 99%
filed 2026-05-21
Item 1.01
This Item 1.01 discloses entry into an Agreement and Plan of Merger between Equity Residential and AvalonBay Communities, Inc., structured as an all-stock merger-of-equals transaction with an exchange ratio of 2.793 Equity Residential Common Shares per AvalonBay share. Both boards have unanimously approved the transaction, which constitutes a material acquisition/change of control requiring shareholder approval and affecting the combined entity's governance, equity awards, and capital structure.
View raw filing on EDGAR →
ERP OPERATING LTD PARTNERSHIP
Exec Compensation
confidence 75%
filed 2026-05-21
Item 5.02
The primary disclosure centers on an Amended and Restated Change in Control Agreement with Mark J. Parrell that modifies his severance formula to 2.25x base salary plus target bonus and equity grant, plus 27 months of benefits continuation. This is a material modification to compensatory arrangements for a named executive officer. While the section also mentions an offer letter for Benjamin W. Schall as incoming CEO, the substantive compensation disclosure focuses on Parrell's amended severance terms.
View raw filing on EDGAR →
ERP OPERATING LTD PARTNERSHIP
M&A activity
confidence 95%
filed 2026-05-21
Item 7.01
Equity Residential and AvalonBay announced entry into a Merger Agreement on May 21, 2026, disclosed via joint press release and investor presentation. This constitutes a material acquisition/change of control event that would significantly affect investor assessment of the registrant's strategic direction and shareholder value.
View raw filing on EDGAR →
ERP OPERATING LTD PARTNERSHIP
M&A activity
confidence 92%
filed 2026-05-21
Item 8.01
The disclosure describes execution of a Merger Agreement and a commitment letter for $2 billion in bridge financing to support the transaction. While technically filed under Item 8.01 (Other Events), the substance is material M&A activity — the commitment letter is ancillary financing documentation supporting a merger. The reference to "in connection with the execution of the Merger Agreement" and the substantial bridge loan commitment ($2 billion) are hallmarks of a material acquisition or merger transaction.
View raw filing on EDGAR →
Hemab Therapeutics Holdings, Inc.
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing financial results for the quarter ended March 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
ADVANCE AUTO PARTS INC
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses financial results for the first quarter ended April 25, 2026 via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →
SHOE CARNIVAL INC
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing "operating and financial results for its first quarter ended May 2, 2026," which is a standard quarterly earnings release. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with Item 2.02 earnings disclosures. This is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
Blackstone Real Estate Income Trust, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 7.01
This Item 7.01 disclosure presents BREIT's Q1 2026 quarterly update, including performance metrics (+2.0% net return), portfolio composition, and strategic positioning. While it contains performance data and forward-looking commentary on real estate markets and BREIT's investment strategy, it does not constitute a formal earnings release (no complete financial statements or standardized earnings metrics), nor does it fit cleanly into other specific event categories. The disclosure is material to investors as it provides substantive updates on fund performance, portfolio allocation, and capital deployment, but the format and content are more consistent with a general investor update than a traditional earnings announcement.
View raw filing on EDGAR →
RTB Digital, Inc.
M&A activity
confidence 95%
filed 2026-05-21
Item 2.01
Item 2.01 explicitly discloses completion of an acquisition or disposition of assets. The filing references incorporation of information from an "Introductory Note" and a proxy statement/prospectus filed January 30, 2026 describing a merger involving RTB, indicating a material M&A transaction has been completed. The disclosure of director conflicts of interest further confirms a significant acquisition event.
View raw filing on EDGAR →
RTB Digital, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 3.02
RTB Digital is disclosing unregistered issuances of equity securities totaling approximately 13.1 million shares (7.7M from convertible debt conversion, 2.1M from warrant exercise, and 3.4M from option exercise) pursuant to Section 4 exemptions from registration. This is a classic dilutive issuance disclosure under Item 3.02, involving multiple tranches of unregistered equity being issued to accredited and sophisticated investors without registration rights, which materially dilutes existing shareholders.
View raw filing on EDGAR →